Keppra and Disseminated intravascular coagulation - from FDA reports


Summary

Disseminated intravascular coagulation is found among people who take Keppra, especially for people who are male, 60+ old , have been taking the drug for < 1 month, also take medication Lamictal, and have Epilepsy . We study 34,747 people who have side effects while taking Keppra from FDA. Among them, 47 have Disseminated intravascular coagulation. Find out below who they are, when they have Disseminated intravascular coagulation and more.

What to expect?

If you take Keppra and have Disseminated intravascular coagulation, find out what symptoms you could have in 1 year or longer.

You are not alone!

Join a support group for people who take Keppra and have Disseminated intravascular coagulation

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>

Keppra

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. (latest outcomes from Keppra 37,187 users)

Disseminated Intravascular Coagulation

Disseminated intravascular coagulation (systemic activation of blood coagulation) has been reported by people with rheumatoid arthritis, preventive health care, high blood pressure, pain, insomnia (latest reports from 16,824 Disseminated intravascular coagulation patients).

On Feb, 27, 2017

34,747 people reported to have side effects when taking Keppra.
Among them, 47 people (0.14%) have Disseminated Intravascular Coagulation


Number of reports submitted per year:

Could Keppra cause Disseminated intravascular coagulation?

Time on Keppra when people have Disseminated Intravascular Coagulation *:

  • < 1 month: 46.67 %
  • 1 - 6 months: 20.0 %
  • 6 - 12 months: 13.33 %
  • 1 - 2 years: 20.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Disseminated Intravascular Coagulation when taking Keppra *:

  • female: 46.67 %
  • male: 53.33 %

Age of people who have Disseminated Intravascular Coagulation when taking Keppra *:

  • 0-1: 0.0 %
  • 2-9: 2.5 %
  • 10-19: 7.5 %
  • 20-29: 20.0 %
  • 30-39: 20.0 %
  • 40-49: 5.0 %
  • 50-59: 10.0 %
  • 60+: 35.0 %

Top conditions involved for these people *:

  • Epilepsy (14 people, 29.79%)
  • Preventive Health Care (8 people, 17.02%)
  • Glioblastoma Multiforme (7 people, 14.89%)
  • Depression (5 people, 10.64%)
  • Acute Promyelocytic Leukaemia (3 people, 6.38%)

Top co-used drugs for these people *:

  • Lamictal (11 people, 23.40%)
  • Tegretol (9 people, 19.15%)
  • Protonix (8 people, 17.02%)
  • Simvastatin (6 people, 12.77%)
  • Depakene (6 people, 12.77%)

Top other side effects for these people *:

  • Fever (16 people, 34.04%)
  • Status Epilepticus (11 people, 23.40%)
  • Thrombocytopenia (10 people, 21.28%)
  • Rhabdomyolysis (10 people, 21.28%)
  • Septic Shock (9 people, 19.15%)

* Approximation only. Some reports may have incomplete information.

** Reports from social media are used.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Disseminated intravascular coagulation when taking Keppra?

Browse all side effects of Keppra

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Disseminated intravascular coagulation

Disseminated intravascular coagulation

Could your condition cause Disseminated intravascular coagulation

Disseminated intravascular coagulation

Related studies

Can you answer these questions?

More questions for: Keppra, Disseminated intravascular coagulation

You may be interested in these reviews

More reviews for: Keppra, Disseminated intravascular coagulation